Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome

Clinical Endocrinology

Volumn 78, Issue 3, 2013, Pages 379-384

  Cinar, Nese ^a   Harmanci, Ayla ^a   Bayraktar, Miyase ^a   Yildiz, Bulent O ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DROSPIRENONE PLUS ETHINYLESTRADIOL; GLUCOSE; INSULIN; LIPID; METFORMIN;

ADOLESCENT; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HIRSUTISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID ANALYSIS; LIPID BLOOD LEVEL; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ANDROSTENES; ETHINYL ESTRADIOL; FEMALE; HUMANS; MALE; METFORMIN; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; THINNESS;

EID: 84872980562     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04415.x     Document Type: Article

References (40)

1. Ehrmann, D.A., (2005) Polycystic ovary syndrome. New England Journal of Medicine, 352, 1223-1236.
2. Legro, R.S., (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocrine Reviews, 24, 302-312. (Pubitemid 36724372)
3. Fauser, B.C., Tarlatzis, B.C., Rebar, R.W., et al,. (2012) Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility, 97, 28-38. e25.
4. Yildiz, B.O., (2008) Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment. Seminars in Reproductive Medicine, 26, 111-120.
5. Vrbikova, J., &, Cibula, D., (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Human Reproduction Update, 11, 277-291. (Pubitemid 40668112)
6. Shulman, L.P., (2002) Safety and efficacy of a new oral contraceptive containing drospirenone. Journal of Reproductive Medicine, 47, 981-984. (Pubitemid 35429885)
7. Guido, M., Romualdi, D., Giuliani, M., et al,. (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. Journal of Clinical Endocrinology and Metabolism, 89, 2817-2823. (Pubitemid 38766371)
8. Pehlivanov, B., &, Mitkov, M., (2007) Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. European Journal of Contraception and Reproductive Health Care, 12, 30-35. (Pubitemid 46466188)
9. Mancini, F., Cianciosi, A., Persico, N., et al,. (2010) Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study. American Journal of Obstetrics and Gynecology, 202, 169. e1-8.
10. Kriplani, A., Periyasamy, A.J., Agarwal, N., et al,. (2010) Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception, 82, 139-146.
11. Lord, J.M., Flight, I.H., &, Norman, R.J., (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. British Medical Journal, 327, 951-953.
12. Baillargeon, J.P., Jakubowicz, D.J., Iuorno, M.J., et al,. (2004) Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility, 82, 893-902. (Pubitemid 39346435)
13. Palomba, S., Falbo, A., Zullo, F., et al,. (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine Reviews, 30, 1-50.
14. Palomba, S., Falbo, A., Giallauria, F., et al,. (2010) Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care, 33, 246-251.
15. Orio, F., Palomba, S., Cascella, T., et al,. (2005) Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. Journal of Clinical Endocrinology and Metabolism, 90, 6072-6076. (Pubitemid 41606527)
16. Orio, F., Manguso, F., Di Biase, S., et al,. (2007) Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. European Journal of Endocrinology, 157, 69-73. (Pubitemid 47162568)
17. Harborne, L., Fleming, R., Lyall, H., et al,. (2003) Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 88, 4116-4123. (Pubitemid 37153708)
18. Maciel, G.A., Soares Junior, J.M., Alves da Motta, E.L., et al,. (2004) Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility, 81, 355-360. (Pubitemid 38223916)
19. Trolle, B., Flyvbjerg, A., Kesmodel, U., et al,. (2007) Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Human Reproduction, 22, 2967-2973. (Pubitemid 351696807)
20. Cibula, D., Fanta, M., Vrbikova, J., et al,. (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction, 20, 180-184.
21. Elter, K., Imir, G., &, Durmusoglu, F., (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction, 17, 1729-1737. (Pubitemid 34790292)
22. Fruzzetti, F., Perini, D., Lazzarini, V., et al,. (2010) Comparison of effects of 3 mg drospirenone plus 20 mug ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertility and Sterility, 94, 1793-1798.
23. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004) Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81, 19-25.
24. Yildiz, B.O., Bozdag, G., Harmanci, A., et al,. (2010) Increased circulating soluble P-selectin in polycystic ovary syndrome. Fertility and Sterility, 93, 2311-2315.
25. Batukan, C., &, Muderris, I.I., (2006) Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertility and Sterility, 85, 436-440. (Pubitemid 43170919)
26. Tfayli, H., Ulnach, J.W., Lee, S., et al,. (2011) Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. Journal of Clinical Endocrinology and Metabolism, 96, 1311-1319.
27. Oelkers, W., Foidart, J.M., Dombrovicz, N., et al,. (1995) Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Journal of Clinical Endocrinology and Metabolism, 80, 1816-1821.
28. Parsey, K.S., &, Pong, A., (2000) An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception, 61, 105-111. (Pubitemid 30236331)
29. Krstevska, B., Dimitrovski, C., Pemovska, G., et al,. (2006) Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. Prilozi, 27, 57-66.
30. Oppelt, P.G., Mueller, A., Jentsch, K., et al,. (2010) The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology & Diabetes, 118, 633-637.
31. Costello, M.F., Shrestha, B., Eden, J., et al,. (2007) Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Human Reproduction, 22, 1200-1209. (Pubitemid 47062785)
32. Velazquez, E.M., Mendoza, S., Hamer, T., et al,. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647-654. (Pubitemid 24145474)
33. Acbay, O., &, Gundogdu, S., (1996) Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertility and Sterility, 65, 946-949. (Pubitemid 26127855)
34. Ehrmann, D.A., Cavaghan, M.K., Imperial, J., et al,. (1997) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 82, 524-530. (Pubitemid 27068623)
35. Morin-Papunen, L.C., Koivunen, R.M., Ruokonen, A., et al,. (1998) Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertility and Sterility, 69, 691-696. (Pubitemid 28188465)
36. Kolodziejczyk, B., Duleba, A.J., Spaczynski, R.Z., et al,. (2000) Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertility and Sterility, 73, 1149-1154. (Pubitemid 30336759)
37. Diamanti-Kandarakis, E., Kouli, C., Tsianateli, T., et al,. (1998) Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. European Journal of Endocrinology, 138, 269-274. (Pubitemid 28154775)
38. Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M., et al,. (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol- cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology and Metabolism, 85, 3161-3168.
39. Ehrmann, D.A., Barnes, R.B., Rosenfield, R.L., et al,. (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, 22, 141-146. (Pubitemid 29028311)
40. Norman, R.J., Masters, L., Milner, C.R., et al,. (2001) Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reproduction, 16, 1995-1998. (Pubitemid 32916235)